Rezaie A R, Olson S T
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.
Biochemistry. 1997 Feb 4;36(5):1026-33. doi: 10.1021/bi9620823.
Lys60f has been proposed to limit the S1' substrate binding site specificity of thrombin to small polar P1' residues by occluding the S1' binding pocket, based on the X-ray crystal structure of thrombin. To test this proposal, we prepared a Lys-->Ala (K60fA) mutant of recombinant thrombin and determined whether this mutation enhanced the reactivity of thrombin with a variant inhibitor [antithrombin (AT)-Denver] and a substrate (protein C) containing poorly recognized P1' Leu residues. AT-Denver in the presence of heparin inhibited K60fA thrombin with a second-order association rate constant [k = 4.2 +/- 0.1) x 10(5) M-1 s-1] that was 3.2-fold faster than thrombin [k = (1.3 +/- 0.1) x 10(5) M-1 s-1]. Wildtype AT (P1' Ser) under the same conditions inhibited K60fA thrombin with a 2.5-fold slower rate constant [k = (1.1 +/- 0.1) x 10(7) M-1 s-1] than thrombin [k = (2.8 +/- 0.1) x 10(7) M-1 s-1]. These results indicate an overall 8.3-fold improvement in the recognition of the P1' Leu of AT-Denver by K60fA thrombin over that of wild-type thrombin; i.e., the K60fA mutation partly overcomes the defect in thrombin inhibition produced by the P1' mutation in AT-Denver. Resolution of the two-step reactions of AT and AT-Denver with wild-type and mutant thrombins revealed that the enhanced recognition of P1' Leu in AT-Denver by K60fA thrombin occurs primarily in the second reaction step in which a noncovalent AT-thrombin encounter complex is converted to a stable, covalent complex. Thrombin K60fA activated Gla-domainless protein C (GDPC) approximately 2- and approximately 4-fold faster than thrombin in the presence and absence of thrombomodulin (TM), respectively, consistent with an improved interaction of the Leu P1' residue with the mutant S1' pocket. In contrast, the mutant thrombin clotted fibrinogen (P1' Gly) approximately 3-fold slower than thrombin. Kinetic analysis revealed that the improvement in the catalytic rate of activation of GDPC by K60fA thrombin in the presence of TM was localized in the second reaction step, as reflected by an approximately 2-fold increase in kcat. Direct binding studies showed that the K60fA mutation minimally affected the affinity of thrombin for Na+, indicating that the changes in S1' site-specificity of K60fA thrombin did not result from altering the allosteric transition induced by Na+. We conclude that Lys60f limits the P1' substrate and inhibitor specificity of thrombin by influencing the size and polarity of the S1' site which thereby affects the stability of the transition state for cleavage of the scissile bond in the second reaction step.
基于凝血酶的X射线晶体结构,有人提出Lys60f通过封闭S1'结合口袋来限制凝血酶的S1'底物结合位点对小的极性P1'残基的特异性。为了验证这一观点,我们制备了重组凝血酶的Lys→Ala(K60fA)突变体,并确定该突变是否增强了凝血酶与变体抑制剂[抗凝血酶(AT)-丹佛]和含有难以识别的P1'亮氨酸残基的底物(蛋白C)的反应活性。在肝素存在下,AT-丹佛抑制K60fA凝血酶的二级缔合速率常数[k = (4.2±0.1)×10⁵ M⁻¹ s⁻¹]比凝血酶快3.2倍[k = (1.3±0.1)×10⁵ M⁻¹ s⁻¹]。在相同条件下,野生型AT(P1'丝氨酸)抑制K60fA凝血酶的速率常数[k = (1.1±0.1)×10⁷ M⁻¹ s⁻¹]比凝血酶慢2.5倍[k = (2.8±0.1)×10⁷ M⁻¹ s⁻¹]。这些结果表明,K60fA凝血酶对AT-丹佛的P1'亮氨酸的识别能力比野生型凝血酶总体提高了8.3倍;即,K60fA突变部分克服了AT-丹佛中P1'突变导致的凝血酶抑制缺陷。对AT和AT-丹佛与野生型和突变型凝血酶的两步反应的解析表明,K60fA凝血酶对AT-丹佛中P1'亮氨酸的增强识别主要发生在第二步反应中,即非共价的AT-凝血酶相遇复合物转化为稳定的共价复合物的过程中。在有和没有血栓调节蛋白(TM)的情况下,凝血酶K60fA激活无Gla结构域的蛋白C(GDPC)的速度分别比凝血酶快约2倍和约4倍,这与亮氨酸P1'残基与突变型S1'口袋的相互作用改善一致。相比之下,突变型凝血酶使纤维蛋白原(P1'甘氨酸)凝固的速度比凝血酶慢约3倍。动力学分析表明,在有TM存在的情况下,K60fA凝血酶激活GDPC的催化速率的提高局限于第二步反应,表现为kcat增加约2倍。直接结合研究表明,K60fA突变对凝血酶与Na⁺的亲和力影响最小,表明K60fA凝血酶S1'位点特异性的变化不是由改变Na⁺诱导的变构转变引起的。我们得出结论,Lys60f通过影响S1'位点的大小和极性来限制凝血酶的P1'底物和抑制剂特异性,从而影响第二步反应中裂解键断裂的过渡态的稳定性。